Corporate Cash Flow Insights
Companies Report Mixed Cash Flow Results, Highlighting Varied Financial Health
Anonymous
Key Points
1
Galecto Ord Shs' free cash flow in the latest quarter was -6.73M, with a 63.88% year-over-year change, signaling meaningful volatility in cash generation from one period to the next.
2
Figure Technology Solutions Inc shows a robust operating cash flow of 62.57M in fiscal 2025, indicating strong cash conversion of earnings to cash, while the corresponding investing activity includes 26.38M spent on capital expenditures in the most recent quarter.
3
Cuprina Holdings (Cayman) Ltd posted a negative operating cash flow of -7.17M in fiscal 2025, with a relatively small capital expenditure outlay of 45.69K, suggesting cash burn with limited reinvestment activity.
4
Bally's Corp shows a sizable capex figure of 225.08M in the most recent quarter, but the snippet does not disclose operating cash flow, illustrating gaps in cash-flow detail availability across the firms covered in this set.
Five publicly traded companies posted sharply different cash flow results, revealing a wide gap between firms generating real cash and those burning through reserves. Figure Technology Solutions led the group with $62.57 million in operating cash flow for fiscal 2025, while Scully Royalty Ltd logged the steepest burn at -$22.86 million, according to TradingKey.
The results highlight a core question for investors: can a company turn its earnings into actual cash? Positive cash flow signals financial strength. Negative cash flow can mean a company is spending more than it earns — sometimes by choice, sometimes by necessity.
Figure Technology Solutions Stands Out With Strong Cash Conversion
Figure Technology Solutions posted $62.57 million in operating cash flow for fiscal 2025 — the only company in this group to show a firmly positive result. The fintech firm, which went public on Nasdaq in September 2025 raising $788 million, saw Q1 2026 revenues reach $167 million, a 92% jump year over year. That kind of revenue growth paired with strong cash flow is rare, according to TradingKey.
Figure also spent $26.38 million on capital expenditures in its most recent quarter. Capex is money spent on physical assets or infrastructure to grow the business. Despite that spending, Figure's cash generation remained robust enough to fund a $200 million share repurchase program — a sign that the company can reward shareholders without borrowing to do so.
Bally's Bets Big on Chicago While Cash Flow Details Stay Murky
Bally's Corp stands out for a different reason: a massive $225.08 million capital expenditure figure in its most recent quarter. That spending is tied to its $1.7 billion permanent Chicago casino project, which hit a structural steel milestone in May 2026. Bally's Q1 2026 operating cash flow came in at $66.67 million, but full-year figures were not disclosed in available summaries, according to TradingKey.
Credit rating agencies are watching closely. Fitch revised Bally's outlook to Negative in June 2026, affirming a 'B-' rating, and warned that the Chicago casino alone requires $200 million in annual spending through 2027. S&P Global lowered Bally's secured debt rating to 'B', citing fixed rent obligations of $56 million per year from sale-leaseback deals that reduce long-term cash flow benefits.
Cuprina and Galecto Burn Cash but Pursue High-Stakes Catalysts
Cuprina Holdings posted -$7.17 million in operating cash flow for fiscal 2025, a -654.49% drop year over year. The company spent just $45,690 on capex, suggesting it is not investing heavily in new assets. Cuprina went public in April 2025, raising $12 million. By November, it had already received a Nasdaq noncompliance notice for its stock falling below $1.00, according to TradingKey.
The picture may shift. In June 2026, Cuprina regained Nasdaq compliance. Days earlier, the FDA granted 510(k) clearance to its MEDIFLY Maggots wound care product — the first U.S. clearance of its kind for a Lucilia cuprina maggot therapy. That regulatory win gives the company a commercial foothold, though turning clearance into cash remains the key challenge. Meanwhile, Galecto — now rebranded as Damora Therapeutics — reported -$6.73 million in operating cash flow, but holds roughly $535 million in cash after a $285 million Series C raise, giving it a runway through 2029, according to TradingKey.
Scully Royalty's Cash Burn Signals a Company Under Pressure
Scully Royalty Ltd posted the worst operating cash flow in the group at -$22.86 million, a -219.27% decline year over year. Despite burning through cash at that pace, Scully spent just $64,500 on capex in its most recent quarter. That combination — heavy cash burn with minimal reinvestment — points to a company facing real financial strain rather than one spending aggressively to grow, according to TradingKey.
Analysts track free cash flow — the money left after capital spending — as a cleaner measure of financial health than net income alone. For companies like Scully and Cuprina, negative free cash flow raises questions about how long they can sustain operations without raising fresh capital. For Figure, strong free cash flow shows it can fund growth, pay down debt, and return cash to shareholders all at once.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
94
Articles
1
Reach
95
A
AnonymousAuthor
